---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-026777"
form_type: "8-K"
ticker: "IVF"
cik: "0001417926"
company_name: "INVO Fertility, Inc."
filed_at: "2026-06-02T12:40:33+00:00"
generated_at: "2026-06-02T12:46:03.935189+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# INVO Fertility FY2025 revenue $6.84M (+5% YoY); net loss improves to $(5.3)M

## Summary
- Revenue $6,841,250, up 5% from $6,532,000; consolidated clinic revenue up 4% to $6.72M.
- Net loss from continuing operations improved to $(5.3)M from $(7.7)M; adjusted EBITDA $(3.2)M vs $(2.2)M.
- Raised $11.5M in gross proceeds from Dec 2025 and Jan 2026 financings; Series C-2 Preferred converted/retired.
- Acquired Indiana-based Family Beginnings in Feb 2026; it had $1.2M revenue and $0.2M net income TTM Sep 2025.
- Patent issued for modified INVOcell device extending protection through 2040; total common shares ~1.8M as of June 2, 2026.

## SEC filing metadata
- accession: 0001493152-26-026777
- form_type: 8-K
- ticker: IVF
- cik: 0001417926
- company_name: INVO Fertility, Inc.
- filed_at: 2026-06-02T12:40:33+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1417926/000149315226026777/0001493152-26-026777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1417926/000149315226026777/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-026777
- JSON: https://secwatch.observer/filing/0001493152-26-026777.json
- Plain text: https://secwatch.observer/filing/0001493152-26-026777.txt

## Source-grounded claims
- claim_id: 30c826a965e0698bb8910d8fce4dbcd51e52acf4
  claim: INVO Fertility, Inc. reported fiscal year 2025 results: revenue $6,841,250, net income $(5.3) million.
  evidence_excerpt: and technologies, today announced fiscal year 2025 financial results. FY2025 Financial Highlights (all metrics compared to FY2024 unless otherwise noted) ● Revenue was $6,841,250, an increase of 5% compared to $6,532,000. ● Consolidated clinic revenue increased 4% to $6,721,057, compared to $6,450,431. ● Revenue from all clinics was $8,021,929, including
  evidence_url: https://www.sec.gov/Archives/edgar/data/1417926/000149315226026777/0001493152-26-026777-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.